BREAKING: U.S. FDA Grants Regular Approval to Selpercatinib for Locally Advanced or Metastatic RET+ NSCLC #lcsm #oncology ow.ly/Wcqn50KPN97

In San Antonio for #SABCS22? Visit Caris at Booth 901 and learn how Caris is revolutionizing precision medicine. Get more info: lnkd.in/gTS5V_5N #breastcancerresearch #molecularprofiling

#Antibiotics do NOT treat viruses, like those that cause colds, #RSV, #flu, or #COVID19. Other medications, like antivirals, can treat viruses. Never pressure your #HCP for antibiotics. Talk to them about other ways you can feel better: bit.ly/3mWYGyv #BeAntibioticsAware

#GU23 ASCO Abs#18👉 Alan H Bryce presents the interim results of the TRITON3 trial 👉Rucaparib significantly improved rPFS vs either docetaxel or abi/enza in BRCA/ATM + mCRPC #prostatecancer. OS trending favorably in BRCA+pts OncoAlert UroToday.com PCF Science Uromigos

BIomarker detection is important for PARPi therapy selection in CRPC #ascogu2023

⚡️ Checkmate 274 trial UPDATE at median follow-up 36.1 months. Median DFS 22.0 months Nivolumab vs 10.9 months w/placebo, [HR] 0.71. ✅Patients w/ PD-L1 ≥1%, Nivolumab median DFS 52.6 mo vs. 8.4 mo w/placebo (HR 0.52) 🤯 ASCO #GU23 OncoAlert

So excited to be able to attend the 1st Annual SoCal Brain Tumor Conference at USC. Josh Neman giving welcome remarks. Caris Life Sciences

Updated analysis showing ctDNA as potentially predictive and prognostic marker after cystectomy in muscle invasive bladder cancer. CtDNA clearance also looks important. New data on relapse rates in ctDNA-ve with be #EAU24 joaquim bellmunt European Urology

Amazing sessions on artificial intelligence in ovarian cancer #Virgostudy, patient/advocate panel providing key aspects to be more inclusive in clinical trials, great FWC Forum! ⁦SGO⁩ ⁦Ginger J. Gardner⁩ ⁦Angeles Secord⁩ #move4her #SGO2024 ⁦Cortney Eakin⁩

Now fully in the era of precision oncology, we should consider testing all gynecologic cancers for HER2. #sgo2024

Mirvetuximab soravtansine improved HRQOL compared with the investigator’s choice of chemotherapy in a PRO from the phase 3 MIRASOL trial for patients with folate receptor-alpha positive, platinum-resistant ovarian cancer. #gyncsm #SGOMtg | SGO cancernetwork.com/view/mirvetuxi…

Have you heard about using spatial transcriptomics for studying the tumor microenvironment in endometrial cancer? 🧬🔬Watch 🎥 for more info! SGO #PowerOfSharedPurpose #SGO2024 #EstefaniaFernandez MD Anderson Cancer Center ASCO OncoAlert Eric Rios-Doria, MD

🚨🥁HOT OFF THE PRESS👉Just in time for ASCO #ASCO24 published in the highest impact factor journal in all of oncology CA: A Cancer Journal for Clinicians American Cancer Society CA: A Cancer Journal for Clinicians 👉Such a delight to share with the world in open access for all to read 💥The evolving

#ASCO24 is tomorrow! Lung Cancer Abstracts not to missed👇 My Top 5 Targeted Therapy abstracts, with key data where available Get your thinking caps on for tomorrow ASCO ESMO - Eur. Oncology IASLC #ASCOLDP22 #ESMOCorrespondents Annals of Oncology #IrishLungCancerCommunity EGFR Resisters KRASKickers

ADC In NSCLC. All drugs in one slide . Excellent slide for quick comparison . ESMO - Eur. Oncology #ESMO24 LARVOL ONCO BRUNO

Keynote lecture by Ash A. Alizadeh, Ash Alizadeh, MD/PhD 🇺🇸 from Stanford University, AACR #AACRliqbio24 Caris Life Sciences Stanford Medicine

Dr. Gʀᴇɢᴏʀʏ Rɪᴇʟʏ addresses waiting for biomarkers in the treatment of NSCLC at #NYLung24. Can be hard to be patient but critically important to avoid giving the wrong treatment. Sequence of treatments have consequences.

Helpful discussion on optimizing the testing journey in NSCLC with Drs. Sanja Dacic, Catherine A. Shu, MD Gʀᴇɢᴏʀʏ Rɪᴇʟʏ at #NYLung24. Pros and cons of reflex testing. Requires thoughtful consideration of each clinical setting.

Is it a myth🐉 that fusions cannot be detected on #LiquidBiopsies🩸? Multiple factors to keep in mind. Dependent on: ⚫️Platform⚙️ 🔵Methodology🔣 🔴Shedding💦 Last few weeks of clinic: 2️⃣FGFR2 fusions in CUP➡️Cholangiocarcinoma 1️⃣RET in HCC ✅Actionable findings exist. Test💯.

🚨 Lung Cancer Updates 2025! Dr. Hamid Mirshahidi, MD (Loma Linda University) shares: 1⃣ "T1 N2A used to be stage 3A, now is a stage 2B." 2️⃣ "A combination of chemoemotherapy preoperatly can help us to make this non-respectable stage treeung cancer as this respectable lung